Ocular Therapeutix (NasdaqGM:OCUL) Conference March 25, 2026 09:30 AM ET Company ParticipantsLisa Walter - VP of Biotech Equity ResearchPravin Dugel - Executive Chairman, President, and CEOLisa WalterGood morning, everyone. I'm Lisa Walter, Biotech Analyst here at RBC Capital Markets. Thanks for joining us at RBC's Ophthalmology Conference. This session, we have Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix. Pravin, thanks so much for joining us today. How are you doing?Pravin D ...

Core Viewpoint - EyePoint Inc has filed a lawsuit against Ocular Therapeutix, alleging the spread of false or misleading information regarding EyePoint's lead experimental eye drug, Duravyu [1][2]. Group 1: Legal Actions - The lawsuit was filed in Middlesex County Superior Court, Massachusetts, accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of consumer protection law [2][3]. - EyePoint is seeking a court order to stop Ocular Therapeutix from making the alleged false statements, demand a public retraction, and claim monetary damages and legal fees [3]. Group 2: Product Development - EyePoint's Duravyu is currently undergoing late-stage studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema, with data for wet AMD expected to be available by mid-2026 [4]. - Ocular Therapeutix's leading drug, Axpaxli, recently met the main goal of a key late-stage trial, demonstrating its effectiveness in helping patients with wet AMD maintain vision compared to Regeneron's Eylea [4].

Ocular Therapeutix is a clinical-stage biopharmaceutical company specializing in innovative drug delivery solutions for eye diseases. The company combines proprietary hydrogel technology with established and novel therapeutics to address unmet medical needs in ophthalmology. Its strategic collaborations and diversified pipeline position it to compete in the high-growth ophthalmic pharmaceutical market.Primary customers include ophthalmologists, eye care centers, and healthcare providers treating ocular dise ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Summary of Ocular Therapeutix FY Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Event**: FY Conference on March 02, 2026 - **Key Speaker**: Pravin U. Dugel, CEO Core Industry Insights - **Industry**: Biopharmaceuticals, specifically focusing on retinal diseases and treatments - **Key Product**: AXPAXLI, a drug aimed at treating retinal diseases, with a focus on its superiority over existing anti-VEGF treatments Key Points and Arguments 1. **Positive Study Outcome**: The SOL-1 study achieved a positive outcome, marking the first superiority study in the retina field to meet its primary endpoint, with a p-value of 0.0006, indicating statistical significance [2][8][25] 2. **Study Design**: The study was conducted under a Special Protocol Assessment (SPA) from the FDA, making it unique and unprecedented in its design [2][25] 3. **Data Transparency**: Ocular Therapeutix provided extensive data (129 slides) to address questions and concerns raised post-study announcement, emphasizing the consistency of the data across various analyses [3][4][5] 4. **Visual Acuity Loss**: The study highlighted the time it takes for significant vision loss to occur, with a focus on the clinical significance of the OCT results, which showed a high degree of disease control [8][20] 5. **Rescue Patients Analysis**: The analysis of patients who required rescue injections indicated that the AXPAXLI drug performed well even in a biased patient population, with results still being favorable compared to EYLEA [17][19] 6. **Superiority Label Importance**: The CEO emphasized the potential for AXPAXLI to receive a superiority label, which would protect its pricing and market position against competitors, particularly in a landscape filled with non-inferiority studies [25][27] 7. **Community vs. Clinical Trial Performance**: The CEO expressed confidence that AXPAXLI would perform better in real-world settings than in clinical trials, as the trial population was designed to lose vision [32][33] 8. **Regulatory Pathway**: Ocular Therapeutix is optimistic about submitting for approval based on a single trial, citing the robustness of their data and the SPA agreement with the FDA [64][65] 9. **Broad Label Expectations**: The company anticipates a broad label for diabetic retinopathy and diabetic macular edema, which would encompass all patients with these conditions [66][67] Additional Important Insights - **Safety Profile**: The CEO addressed concerns regarding floaters and cataracts, clarifying that reported floaters were drug particles observed by physicians and did not affect vision [60][63] - **Market Positioning**: The company aims to differentiate AXPAXLI from competitors like EYLEA and Vabysmo, highlighting its longer duration of effect and potential for better patient outcomes [48][49] - **Physician Perspectives**: There is a disconnect between analysts' focus on labeling and physicians' practical use of the drug, with physicians prioritizing treatment efficacy over label specifics [22][23][27] This summary encapsulates the key discussions and insights from the Ocular Therapeutix conference call, focusing on the company's recent study outcomes, product positioning, and future regulatory strategies.

Ocular Therapeutix (NasdaqGM:OCUL) Conference Call Summary Company Overview - **Company**: Ocular Therapeutix - **Product**: AXPAXLI (OTX-TKI) - **Indication**: Wet Age-related Macular Degeneration (AMD) - **Clinical Trial**: SOL-1 Phase 3 clinical trial Key Points Industry and Product Insights - AXPAXLI demonstrated sustained VEGF suppression with activity observed in 66% of treated subjects for up to 12 months, which is unprecedented compared to competitors [4][5] - The drug's mechanism of action involves blocking all VEGF receptors intracellularly, providing a more comprehensive blockade than current anti-VEGF therapies [8][9] - AXPAXLI utilizes the ELUTYX hydrogel platform for controlled drug delivery, allowing for sustained release over 9-12 months without surgical intervention [10][11] Clinical Trial Results - The SOL-1 trial enrolled 344 subjects, primarily with good baseline vision (average 20/25) [13] - At week 36, 74.1% of AXPAXLI subjects maintained vision (loss of fewer than 15 ETDRS letters) compared to 55.8% in the aflibercept arm, showing a statistically significant difference (p-value of 0.0006) [14] - By week 52, 65.9% of AXPAXLI subjects maintained vision, with a p-value of less than 0.0001, indicating sustained disease control [14] - AXPAXLI also showed superior anatomical control, with 55.9% of subjects maintaining central subfield thickness within 30 microns of baseline at week 36 [15] Safety Profile - No serious adverse events related to treatment were reported, and the safety profile was deemed reassuring by clinicians [18] - The most common non-serious ocular event was vitreous floaters (12.4%), which were not associated with adverse visual outcomes [19][20] - Cataract rates (7.1%) were consistent with other wet AMD trials and not considered alarming [20] Regulatory and Commercialization Strategy - Ocular Therapeutix plans to submit a New Drug Application (NDA) based on SOL-1 data alone, leveraging the FDA's recent guidance allowing for approval based on a single pivotal trial [23][24] - The trial was designed in alignment with FDA guidelines, ensuring unbiased evidence of efficacy and durability [24] - The company is preparing for commercialization, with a capable sales force already in place from its existing product, DEXTENZA [30] Market Potential and Adoption - AXPAXLI is expected to significantly reduce the treatment burden for patients, potentially extending treatment intervals from every 4-6 weeks to every 3-4 months [51] - Clinicians expressed high confidence in adopting AXPAXLI for various patient populations, including treatment-naive patients and those currently on frequent anti-VEGF injections [49][56] - The drug is anticipated to improve long-term outcomes by reducing fibrosis and atrophy, which are common complications in wet AMD [63] Conclusion - AXPAXLI represents a transformative advancement in the treatment of wet AMD, with strong clinical efficacy, a reassuring safety profile, and a strategic plan for regulatory approval and market entry [5][26]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy [2] - Major firms like PwC and McKinsey acknowledge that AI could unlock multi-trillion-dollar opportunities, reinforcing the technology's economic significance [3] Company and Industry Analysis - A breakthrough in AI technology is driving interest among hedge funds and top investors, with a particular under-owned company identified as pivotal to this $250 trillion revolution [4] - The technology landscape is being shaped by significant investments from industry leaders, including Bill Gates and Larry Ellison, who recognize AI's potential to impact various sectors such as healthcare and education [8] - The narrative suggests that while established companies like Nvidia and Tesla are noteworthy, a smaller company is quietly advancing critical technology that underpins the AI revolution [6]

Core Thesis - Ocular Therapeutix, Inc. (OCUL) is experiencing renewed acquisition speculation, particularly from Sanofi, which may be preparing a significantly higher bid of around $30 per share, compared to a previous offer of $16 that was rejected [2][3] Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases and other eye conditions using bioresorbable hydrogel-based formulation technology [2] Acquisition Speculation - Sanofi's urgency to acquire OCUL is driven by the impending loss of exclusivity for its blockbuster drug Dupixent in 2031, with expected revenues of approximately $18 billion in 2025 [3] - Ocular's pipeline, especially in wet AMD and diabetic eye disease, presents Sanofi with access to a neovascular market exceeding $15 billion [3] Investor Positioning - Investors are anticipating various outcomes, with a bullish scenario suggesting that strong trial results could lead Sanofi to offer $25 or more per share, while a base-case scenario could see a deal completed in the $18–$22 range [4] - This positioning indicates significant upside potential for shareholders from current levels [4] Market Volatility and Future Prospects - OCUL has shown typical biotech volatility amid speculation, but its strong fundamentals and high-value pipeline position the company well for meaningful returns, whether through acquisition or continued development of its therapies [5] - Upcoming top-line results on February 17 are expected to be a pivotal catalyst, potentially unlocking substantial value for investors and reinforcing OCUL's growth narrative in ophthalmology [5]

Core Insights - Ocular Therapeutix, Inc. is set to participate in multiple investor conferences in March 2026, showcasing its commitment to engaging with the investment community [1][2][3] Conference Participation - The company will present at the TD Cowen 46 Annual Health Care Conference on March 2, 2026, with a fireside chat led by Pravin U. Dugel, MD, from 9:10 to 9:40 AM ET in Boston, MA [2] - Ocular will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami, FL [2] - Another fireside chat is scheduled for the Citizens Life Sciences Conference on March 11, 2026, from 9:00 to 9:25 AM ET, again featuring Pravin U. Dugel, MD [2] - The Barclays 28 Annual Global Healthcare Conference will take place on March 11, 2026, in Miami, FL [3] - The RBC Capital Markets Ophthalmology Conference is set for March 24, 2026, with a virtual fireside chat from 9:30 to 10:00 AM ET, presented by Pravin U. Dugel, MD [3] Product Pipeline - Ocular Therapeutix is focused on redefining the retina experience with its investigational product AXPAXLI™ (OTX-TKI), currently in Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinal disease [4] - The company’s commercial product DEXTENZA is an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, as well as ocular itching associated with allergic conjunctivitis [5] - Ocular is also advancing its investigational product OTX-TIC, a travoprost intracameral hydrogel that has completed Phase 2 trials for open-angle glaucoma or ocular hypertension, with next steps currently under evaluation [5]

Core Insights - Ocular Therapeutix will present detailed results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration at the 49th Macula Society Annual Meeting on February 27, 2026 [1][2] - An investor webcast is scheduled for March 2, 2026, to discuss the SOL-1 data presented at the meeting [1][3] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [5] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal diseases, currently in Phase 3 trials for wet AMD and diabetic retinal disease [5] - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [6]